



**Supplementary Figures:**

**Supplementary Figure S1. Proportion of patients with radiographic progression ( $\Delta$ SHS>3) among those grouped according to the MBDA score at multiple time-points.** Proportion of radiographic progressors from BL to Year 1 (left bar-graph) and from BL to Year 2 (middle bar-graph) among patients with low, moderate or high MBDA score at Month 3. Proportion of radiographic progressors from Year 1 to Year 2 among patients with low, moderate or high MBDA score at Year 1 (right bar-graph).



**Supplementary Figure S2. Radiographic progression ( $\Delta$ SHS>5) among 3 therapy groups (triple therapy group, anti-TNF treatment group and MTX-responders) stratified by CRP categories at multiple time-points.** Left and middle bar-graphs represent proportion of patients with 2-year radiographic progression stratified by the CRP at BL and Month 3, respectively. Right bar-graph shows radiographic progression from Year 1 to Year 2 among patients stratified by CRP at Year 1.



**Supplementary Figure S3. Distribution of the MBDA score, CRP and ESR against change of SHS.** The MBDA score, CRP and ESR at BL (A) and at Month 3 (B) are plotted against data on  $\Delta$ SHS from BL to Year 2. The MBDA score, CRP and ESR at Year 1 are plotted against delta-SHS from Year 1 to Year 2 (C). The horizontal dashed line illustrates the threshold value for radiographic progression ( $\Delta$ SHS>5) and non-progression ( $\Delta$ SHS $\leq$ 5). The vertical dashed lines indicate the threshold values for low/moderate/high levels of the MBDA score, CRP and ESR, respectively.

